Posted by Michael Wonder on 14 Jul 2022
Zai Lab announces acceptance by China’s NMPA of the BLA for efgartigimod for patients with generalised myasthenia gravis
13 July 2022 - Efgartigimod alfa injection is the first accepted BLA submission of an FcRn antagonist for generalised myasthenia gravis patients in China.
Zai Lab today announced that China’s National Medical Products Administration has accepted the biologics license application for efgartigimod alfa injection, a first in class neonatal Fc receptor antagonist, for the treatment of adult patients with generalised myasthenia gravis.
